Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

14.00 EUR

+0.72 %

5,598 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

+0.72 %
-4.44 %
+5.66 %
+36.59 %
+77.22 %
+70.73 %
+229.80 %
+79.53 %
-97.69 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
100.99M EUR
Turnover
10.89K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Reduce
Target price
Updated
18.08.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 18.08.2025

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
The flurry of December sales announcements seems to have misfired, but not to worry. The latest response written by @Mikko_Karvinen_Nexst to the thread was so cryptic that I, for one, haven’t been able to interpret it as a denial, nor as a confirmation. It might be, or then again...
23 hours ago
by Mark_Renton
38
Startups are always short on cash. This is likely a good deal for both parties and for Nexstim, probably even better than the original all-cash deal. Now Nexstim gets to become a shareholder in Sinaptica’s story, and with that million-euro investment, it will be quite a significant...
1 hour ago
by Kyhnykeisari
24
Well, one more press release for the Christmas stocking. nexstim.com Nexstim - Press-release
1 hour ago
by Mark_Renton
20
Those deals are clearly ones that do not fall into the Brainlab category. In fact, for over two months, there hasn’t been any announcement regarding Brainlab category deals. The last deal that might be in the Brainlab category was made on Oct 7th. Since then, the reported deals have...
19 hours ago
by Jatast
12
For me, Mikko’s announcement was exceptionally clear: sales will be reported quarterly in the future (I expect exceptions would be made for potential one-off deals involving multiple machines). Thanks indeed to Mikko for clarifying this matter. And I agree, I don’t need information...
21 hours ago
by AccionHombre
11
The overall deal is such that a decent amount of cash will certainly flow in as equipment is delivered and recurring revenue is generated. At another time, that million would have been more significant for Nexstim’s cash position, but since we are turning a profit this year anyway...
1 hour ago
by Jatast
8
Sinaptica appointed a Scientific Advisory Board. Yahoo Finance Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together... Sinaptica Therapeutics Scientific Advisory Board Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices...
15 hours ago
by Jatast
8
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.